| |
| |
|
| Insider
Information: |
Sidransky David |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
843,567 |
|
|
Indirect Shares
|
226 |
|
|
| Direct
Value |
$3,485,066 |
|
|
|
Indirect Value
|
$96 |
|
|
| Total
Shares |
843,793 |
|
|
| Total
Value |
$3,485,161 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
0
|
|
Stock
price went up :
|
3
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
3.0
|
0.0
|
| Percentage
Gain/Loss : |
 9.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Champions Biotechnology Inc |
CSBR |
Director |
2022-10-12 |
767,043 |
|
0 |
Premium* |
|
|
KV Pharmaceutical Co |
KVPHQ |
Director |
2013-09-16 |
0 |
2010-07-02 |
0 |
Premium* |
|
|
Epicept Corp |
IMNP |
Director |
2015-01-08 |
21,699 |
2013-08-25 |
0 |
Premium* |
|
|
Advaxis Inc |
ADXS |
Director |
2023-01-19 |
93 |
2023-01-19 |
46 |
Premium* |
|
|
Akari Therapeutics Plc |
AKTX |
Director |
2015-01-01 |
54,732 |
|
0 |
Premium* |
|
|
Orgenesis Inc |
ORGS |
Director |
2020-05-07 |
0 |
2020-05-20 |
180 |
Premium* |
|
|
Ayala Pharmaceuticals, Inc. |
AYLA |
Director |
2020-05-08 |
0 |
2023-01-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
41 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ORGS |
Orgenesis Inc |
Director |
– • – |
2020-05-13 |
4 |
B |
$5.96 |
$417 |
I/I |
70 |
170 |
2.02 |
% |
|
| ORGS |
Orgenesis Inc |
Director |
– • – |
2020-05-20 |
4 |
B |
$6.98 |
$70 |
I/I |
10 |
180 |
2.02 |
% |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2020-07-07 |
4 |
B |
$9.60 |
$10 |
I/I |
1 |
226 |
2.02 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2020-07-17 |
4 |
B |
$11.86 |
$47 |
I/I |
4 |
230 |
2.02 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2020-08-14 |
4 |
B |
$11.07 |
$55 |
I/I |
5 |
235 |
2.02 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2020-09-11 |
4 |
B |
$10.07 |
$101 |
I/I |
10 |
245 |
2.02 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2020-09-14 |
4 |
B |
$10.70 |
$11 |
I/I |
1 |
246 |
2.02 |
- |
|
| CSBR |
Champions Biotechnology I... |
Director |
– • – |
2020-10-16 |
4 |
D |
$9.01 |
$91,001 |
D/D |
(10,100) |
748,234 |
0 |
- |
|
| CSBR |
Champions Biotechnology I... |
Director |
– • – |
2020-10-16 |
4 |
OE |
$5.46 |
$91,002 |
D/D |
16,667 |
758,334 |
0 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2020-12-23 |
4 |
B |
$11.56 |
$46 |
I/I |
4 |
250 |
2.02 |
- |
|
| CSBR |
Champions Biotechnology I... |
Director |
– • – |
2021-10-15 |
4 |
A |
$10.08 |
$26,500 |
D/D |
2,629 |
762,272 |
0 |
- |
|
| CSBR |
Champions Biotechnology I... |
Director |
– • – |
2021-10-15 |
4 |
OE |
$1.59 |
$26,501 |
D/D |
16,667 |
764,901 |
0 |
- |
|
| CSBR |
Champions Biotechnology I... |
Director |
– • – |
2022-10-12 |
4 |
OE |
$3.21 |
$26,749 |
D/D |
8,333 |
770,605 |
0 |
- |
|
| CSBR |
Champions Biotechnology I... |
Director |
– • – |
2022-10-12 |
4 |
D |
$7.51 |
$26,751 |
D/D |
(3,562) |
767,043 |
0 |
- |
|
| ADXS |
Advaxis Inc |
Director |
– • – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
I/I |
46 |
46 |
0 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
Director |
– • – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(250) |
0 |
0 |
- |
|
41 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
